Introducing the plain language in silico medicine glossary
This glossary translates complex, technical language into terms understandable by non experts, aiming to empower patients and the public with a clearer understanding of in silico medicine and its potential impact on healthcare.
Explore the glossary here
We recognize that language evolves, and we welcome your feedback to help us refine and expand this dynamic resource. Together, let’s make in silico medicine more accessible for everyone!
AUTHORS
- Cyrille Thinnes, MBA, DPhil; University of Galway & APC Microbiome Cork, Ireland; VPH Institute; Avicenna Alliance
- Martha De Cunha-Burgman, MSc; Edwards Life Sciences; Avicenna Alliance
- Alissa Hanna, Edwards LifeSciences; Avicenna Alliance
- Marlène Mengoni, PhD; University of Leeds, United Kingdom; VPH Institute; Avicenna Alliance
- Thierry Marchal, MSc; Ansys; Avicenna Alliance
- Davide Montesarchio, PhD; VPH Institute; Avicenna Alliance
- Janaki Raman Rangarajan, PhD; VPH Institute; Avicenna Alliance
- Bernard Staumont, Ir, PhD; Université de Liège, Belgium; VPH Institute; Avicenna Alliance
- Anne Thorez; Voisin Consulting Life Sciences; Avicenna Alliance
- Zita van Horenbeeck, KU Leuven, Belgium; VPH Institute; Avicenna Alliance
- Steven Levine, PhD; Dassault Systèmes; Avicenna Alliance
on behalf of the Public & Patient Involvement task force of the Avicenna Alliance Policy Development Working Group.
DOI: https://doi.org/10.5281/zenodo.14695325
